Norges Bank’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Norges Bank’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-153,492	Closed	-$16.5M	–	2136
2023 Q1	$16.5M	Buy	153,492 +90,992	+146%	+$10.5M	﹤0.01%	1364
2022 Q4	$6.88M	Buy	+62,500	New	+$4.05M	﹤0.01%	1684
2022 Q3	–	Sell	-488,745	Closed	-$13.8M	–	2148
2022 Q2	$13.8M	Sell	488,745 -399,244	-45%	-$11.6M	﹤0.01%	1414
2022 Q1	$33.5M	Buy	887,989 +282,545	+47%	+$11.2M	0.01%	1100
2021 Q4	$23.9M	Buy	605,444 +213,492	+54%	+$6.68M	﹤0.01%	1378
2021 Q3	$9.29M	Hold	391,952	–	–	﹤0.01%	1790
2021 Q2	$9.63M	Hold	391,952	–	–	﹤0.01%	1793
2021 Q1	$7.16M	Buy	+391,952	New	+$8.09M	﹤0.01%	1861

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Norges Bank's RXDX Position: Q2 2023 in Review

Norges Bank sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 153,492 shares — an estimated $16.5M sold.

Norges Bank first reported a position in RXDX in Q1 2021 and held it in 8 quarters. The position peaked at $33.5M in Q1 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Norges Bank reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Norges Bank sold 153,492 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $16.5M.
Norges Bank first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2021 and held it in 8 quarters.
Norges Bank's Prometheus Biosciences, Inc. Common Stock position peaked at $33.5M in Q1 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Norges Bank's 13F filing for Q2 2023, filed 14 Aug 2023.